[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Crispr Therapeutics Ag (CRSP)

Crispr Therapeutics Ag (CRSP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,669,096
  • Shares Outstanding, K 96,449
  • Annual Sales, $ 3,510 K
  • Annual Income, $ -581,600 K
  • EBIT $ -646 M
  • EBITDA $ -627 M
  • 60-Month Beta 1.74
  • Price/Sales 1,386.28
  • Price/Cash Flow N/A
  • Price/Book 2.68

Options Overview Details

View History
  • Implied Volatility 57.82% (+3.57%)
  • Historical Volatility 61.31%
  • IV Percentile 22%
  • IV Rank 25.87%
  • IV High 83.16% on 10/15/25
  • IV Low 48.98% on 02/19/26
  • Expected Move (DTE 5) 2.14 (4.42%)
  • Put/Call Vol Ratio 1.19
  • Today's Volume 3,552
  • Volume Avg (30-Day) 3,517
  • Put/Call OI Ratio 0.64
  • Today's Open Interest 70,956
  • Open Int (30-Day) 68,889
  • Expected Range 46.27 to 50.55

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.12
  • Number of Estimates 9
  • High Estimate $-0.81
  • Low Estimate $-1.31
  • Prior Year $-1.29
  • Growth Rate Est. (year over year) +13.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
48.25 +0.33%
on 05/15/26
59.16 -18.17%
on 04/17/26
-8.35 (-14.71%)
since 04/15/26
3-Month
44.12 +9.72%
on 03/30/26
61.76 -21.62%
on 02/26/26
-4.66 (-8.78%)
since 02/13/26
52-Week
35.38 +36.83%
on 05/29/25
78.48 -38.32%
on 10/08/25
+12.10 (+33.32%)
since 05/15/25

Most Recent Stories

More News
CRISPR Therapeutics Enters 'Second Phase' as CASGEVY Momentum Builds, Pipeline Data Looms

CRISPR Therapeutics (NASDAQ:CRSP) Chief Executive Officer Sam Kulkarni said the company is entering a “second phase” as it moves beyond the initial launch of CASGEVY and prepares for data from multiple...

CRSP : 48.41 (-4.04%)
CRISPR Therapeutics Approaches Its First Earnings With Casgevy Revenue Actually Flowing Through

Barchart Research What to Expect from CRSP Earnings CRSP Generated May 4, 2026 Current Price $53.58 EPS Estimate $$-1.14 Consensus Rating Moderate Buy Average Move 3.85% CRISPR Therapeutics Approaches...

CRSP : 48.41 (-4.04%)
3 Biotech Stocks That Could Benefit from the Patent Cliff

Biotech M&A is surging ahead of a $300B patent cliff. Here are 3 gene-editing stocks investors are watching as potential acquisition targets

BEAM : 27.93 (-5.42%)
CRSP : 48.41 (-4.04%)
MRK : 111.38 (-1.79%)
BMY : 57.00 (+0.41%)
NTLA : 13.67 (+4.43%)
3 ETFs to Buy Now If You Want to Invest Directly in OpenAI

Cathie Wood’s ARK Invest is giving retail investors a rare shot at OpenAI, bringing pre-IPO AI exposure into ARKK, ARKW, and ARKF

ARKW : 143.11 (-3.07%)
$SPX : 7,408.50 (-1.24%)
CRCL : 114.00 (-7.98%)
COIN : 195.43 (-7.82%)
ARKK : 74.90 (-3.97%)
SHOP : 100.28 (+2.94%)
ARKF : 40.70 (-3.07%)
TSLA : 422.24 (-4.75%)
CRSP : 48.41 (-4.04%)
AMD : 424.10 (-5.69%)
XYZ : 70.36 (-1.64%)
TEM : 43.93 (-3.41%)
CRISPR Therapeutics: The Fundamental Standard-Bearer in a Fractured Genomic Sector

With $116 million in FY2025 product revenue and a $2.0 billion cash reserves, CRSP has separated itself from pre-commercial peers — but the path forward demands clear eyes on both opportunity and risk....

CRSP : 48.41 (-4.04%)
EDIT : 2.62 (-8.07%)
NTLA : 13.67 (+4.43%)
This Cathie Wood Stock Is Down 36% Over the Past 2 Years. She Still Can’t Get Enough.

Cathie Wood recently added to her position in CRISPR Therapeutics stock.

CRSP : 48.41 (-4.04%)
ARKG : 28.15 (-3.53%)
ARKK : 74.90 (-3.97%)
CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows

Get context for CRISPR Therapeutics’ Q4 results: CASGEVY launch economics, cash runway, pipeline upside, and the technical level investors should watch.

CRSP : 48.41 (-4.04%)
MS : 192.51 (-1.04%)
VRTX : 436.95 (-2.99%)
Studies test whether gene-editing can fix high cholesterol. For now, take your medicine

Scientists are testing an entirely new way to fight heart disease: whether gene editing might offer a one-time fix for high cholesterol

CRSP : 48.41 (-4.04%)
This Leading Gene-Editing Stock Could Be Going Private. Should You Buy Its Shares First?

CRISPR Therapeutics is the subject of strong buyout speculation after earning FDA approval for a breakthrough gene-editing therapy.

CRSP : 48.41 (-4.04%)
VRTX : 436.95 (-2.99%)
Healthcare's Shift to Prevention Gains Momentum as Markets Reach Critical Mass

Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – Longevity science advances reveal how genes from supercentenarians can reverse cardiac aging[1], while...

HUM : 305.12 (+1.25%)
AVAI : 0.3250 (+3.24%)
CRSP : 48.41 (-4.04%)
VRTX : 436.95 (-2.99%)
MNKD : 3.09 (-4.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

CRISPR Therapeutics AG is a leading gene editing company focused on developing CRISPR/Cas9-based therapeutics. The company is rapidly leveraging its CRISPR/Cas9 gene-editing platform to make therapies for the treatment of hemoglobinopathies, cancer, diabetes and other diseases.

See More

Key Turning Points

3rd Resistance Point 52.02
2nd Resistance Point 51.24
1st Resistance Point 49.82
Last Price 48.41
1st Support Level 47.62
2nd Support Level 46.84
3rd Support Level 45.42

See More

52-Week High 78.48
Fibonacci 61.8% 62.02
Fibonacci 50% 56.93
Fibonacci 38.2% 51.84
Last Price 48.41
52-Week Low 35.38

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.